Wellington Management Group LLP grew its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 24.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,229,882 shares of the company's stock after purchasing an additional 634,099 shares during the period. Wellington Management Group LLP owned about 5.91% of Dianthus Therapeutics worth $314,849,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in DNTH. BlackRock Inc. acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at about $401,990,000. Vestal Point Capital LP increased its holdings in Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after buying an additional 1,499,931 shares during the last quarter. Vanguard Group Inc. raised its position in Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company's stock valued at $84,417,000 after acquiring an additional 406,254 shares in the last quarter. TCG Crossover Management LLC raised its position in Dianthus Therapeutics by 11.7% during the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company's stock valued at $65,975,000 after acquiring an additional 175,000 shares in the last quarter. Finally, State Street Corp lifted its stake in Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company's stock valued at $62,129,000 after acquiring an additional 836,571 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, CEO Marino Garcia sold 166,000 shares of the firm's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a total value of $17,946,260.00. Following the transaction, the chief executive officer directly owned 65,292 shares in the company, valued at approximately $7,058,718.12. This trade represents a 71.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Anne Mcgeorge sold 7,750 shares of Dianthus Therapeutics stock in a transaction on Monday, August 10th. The stock was sold at an average price of $109.01, for a total transaction of $844,827.50. Following the completion of the transaction, the director owned 1,250 shares in the company, valued at $136,262.50. This trade represents a 86.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 260,554 shares of company stock worth $27,211,775 in the last ninety days. 3.02% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Several research firms have commented on DNTH. Guggenheim reissued a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. TD Cowen reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reiterated an "outperform" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Raymond James Financial reissued a "strong-buy" rating and set a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Finally, Wall Street Zen upgraded Dianthus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $124.27.
View Our Latest Analysis on Dianthus Therapeutics
Dianthus Therapeutics Price Performance
Shares of Dianthus Therapeutics stock opened at $105.84 on Monday. The stock has a market capitalization of $5.79 billion, a P/E ratio of -25.50 and a beta of 1.22. The stock has a 50 day moving average price of $103.59 and a two-hundred day moving average price of $87.32. Dianthus Therapeutics, Inc. has a 12-month low of $22.81 and a 12-month high of $117.88.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.
About Dianthus Therapeutics
(
Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
